Exevir’s XVR-013m demonstrates neutralization potency against SARS-CoV-2 variant JN.1
June 5, 2024
Exevir Bio BV has demonstrated that its antibodies are potent in neutralizing the SARS-CoV-2 variant JN.1, the parental strain of the currently most dominantly circulating variants worldwide.